July 18, 2024 10:32 AM EDTUpdated 04:32 PM
Deals
R&D

J&J ditch­es epilep­sy de­vel­op­ment with Ad­dex, blind­sid­ing 20-year part­ner

Kyle LaHucik

Senior Reporter

John­son & John­son has dis­con­tin­ued in­vest­ment in an epilep­sy pro­gram out of 20-year part­ner Ad­dex Ther­a­peu­tics a few months af­ter the Gene­va-based biotech’s drug flunked …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

Jim Wilson's Gem­ma­Bio rais­es $34M to com­mer­cial­ize gene ther­a­pies for rare dis­eases

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

A service from the Financial Times